Compare LGCB & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LGCB | HIND |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 28.0M |
| IPO Year | 2023 | 2016 |
| Metric | LGCB | HIND |
|---|---|---|
| Price | $2.06 | $5.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 76.6K | N/A |
| Earning Date | 07-03-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,993,265.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.80 | N/A |
| 52 Week Low | $1.22 | N/A |
| 52 Week High | $6.83 | N/A |
| Indicator | LGCB | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 44.10 |
| Support Level | $1.85 | $4.81 |
| Resistance Level | $2.12 | $5.37 |
| Average True Range (ATR) | 0.13 | 0.37 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 65.55 | 54.02 |
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.